Latest Breaking News On - Microbiome ecosystem - Page 8 : vimarsana.com

MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients Responses to Immunotherapies Seite 1

31.10.2023 - Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced today . Seite 1

United statesSan diegoNathalie corvaiaSociety for immunotherapy of cancerRegulatory newsMicrobiome ecosystemAnnual meetingArtificial intelligenceChief scientific officerPresentation detailsExhibit hallsMaat pharma chartAat pharma kursAat pharma aktie

MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013

MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Indiens wirtschaftIhre chancenEarly access programSenior pr corporate communicationsTrophic communications corporateEarly access program of maaData safety monitoring boardOverall response rateMicrobiome ecosystemGraft versus host diseaseGastrointestinal overall response rateOne year overall survivalMaat pharmaMicrobiome ecosystem therapiesEuronext parisInvestor relations

MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

LYON, France, October 09, 2023 Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced an increase in the resources allocated to the liquidity contract with the brokerage firm Kepler Cheuvreux.

Kepler cheuvreuxEuropean parliamentCorporate communicationsSenior pr corporate communicationsTrophic communicationsCommission delegated regulationRegulatory newsMicrobiome ecosystemMaat pharmaGeneral meetingFrench commercial codeMicrobiome ecosystem therapiesEuronext parisInvestor relationsMedia relationsBiotechnology company

MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Keple

LYON, France (BUSINESS WIRE) $MAAT Regulatory News:MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced an increase in the resources allocat.

Kepler cheuvreuxCommission delegated regulationTrophic communicationsEuropean parliamentCorporate communicationsSenior pr corporate communicationsRegulatory newsMicrobiome ecosystemMaat pharmaGeneral meetingFrench commercial codeMicrobiome ecosystem therapiesEuronext parisInvestor relationsCommunications manager

MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Kepler cheuvreuxTrophic communications corporateSenior pr corporate communicationsEuropean parliamentCommission delegated regulationRegulatory newsMicrobiome ecosystemMaat pharmaGeneral meetingFrench commercial codeMicrobiome ecosystem therapiesEuronext parisInvestor relationsCommunications managerAktien sie